Abstract
Objective: To analyze, through a narrative review, the impact of the use of Hormone therapy (HT) on the quality of life of women in menopause and as a risk factor for the development of breast cancer, as well as to discuss how the most used therapeutic options, taking into account the improvement in the patients' quality of life. Bibliographic review: Menopause denounces the end of the woman's reproductive period, with decreased ovarian follicular activity. This period is marked by hormonal instabilities and marked symptoms that make many women seek HT as a form of treatment. However, an HRT can affect breast tissue and results in a neoplasm, one dependent on the distribution and time of use, in addition to possible risk factors for breast cancer. Final considerations: It is concluded that the hormone therapy is associated with an increased risk of developing breast cancer, this risk attributed mainly to the progestogens medroxyprogesterone, norethisterone and levonorgestrel. The discontinuation of the use of these tends to decrease the risks and, in general, their administration is not recommended for a period exceeding five years.